Valuence Merger I's Comment on Sales, Marketing and Customers
The company engages with targets in Asia, excluding China, Hong Kong, and Macau, focusing on sectors such as sustainable technology, renewable energy, advanced transportation, digital transformation, clean industrial processes, new materials, and advanced healthcare. It notes significant growth in ESG bonds and sustainable investments in South Korea and Japan. Aging populations in countries including South Korea, Japan, Singapore, Indonesia, and Malaysia drive investments in healthcare research and development, particularly in pharmaceuticals, medical devices, and AI healthcare tools. Key therapeutic areas include oncology, cardiology, infectious disease, immunology, and chronic diseases such as obesity, diabetes, Alzheimer's, fatty liver disease, chronic kidney disease, and idiopathic pulmonary fibrosis. The company identifies opportunities in oncology involving antibody drug conjugates, protein degradation targets, immunotherapies, cancer vaccines, and fatty acid synthase (FASN) inhibitors.
Valuence Merger I’s Comment on Sales, Marketing and Customers
The company engages with targets in Asia, excluding China, Hong Kong, and Macau, focusing on sectors such as sustainable technology, renewable energy, advanced transportation, digital transformation, clean industrial processes, new materials, and advanced healthcare. It notes significant growth in ESG bonds and sustainable investments in South Korea and Japan. Aging populations in countries including South Korea, Japan, Singapore, Indonesia, and Malaysia drive investments in healthcare research and development, particularly in pharmaceuticals, medical devices, and AI healthcare tools. Key therapeutic areas include oncology, cardiology, infectious disease, immunology, and chronic diseases such as obesity, diabetes, Alzheimer's, fatty liver disease, chronic kidney disease, and idiopathic pulmonary fibrosis. The company identifies opportunities in oncology involving antibody drug conjugates, protein degradation targets, immunotherapies, cancer vaccines, and fatty acid synthase (FASN) inhibitors.
Sources:
Valuence Merger Corp I’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Valuence Merger Corp I’s corporate clients.
For your research, we’ve provided 9 tables on Valuence Merger Corp I corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
